Skip Fleshman - Profile and Investment Details

Investor Profile

Skip Fleshman is a Micro VC, Venture Capital, Investor based in United States with a diverse investment portfolio that includes companies such as Indi Molecular, ICON Aircraft, CardioGen Sciences, Chimerix, CardioDx, Esperion Therapeutics, LiquidM, The Activity Exchange (AchieveMint), Signal Vine, Provade, Inc., Proteus Digital Health, OfferIQ, Carta Healthcare, RallyPoint, Welldoc, Freenome, Audentes Therapeutics, Servo Software, InCarda Therapeutics, Rapidscan Pharma Solutions, Unnatural Products, Maverix Biomics, Huiseoul, HealthTap, Tradeo, Arterys, Ooma, Mightier, ViewPoint Therapeutics, Aegis Surgical, Stratavia, Benefitter, Properly, Biomimedica, Profusa, Thunder, Mozio, Sensomics, Amygdala Neuroscience, ImmunoCellular Therapeutics, Outcomes4Me, Evidation Health, Lark, Womply, Twist Bioscience, Terra Bella, UniKey Technologies, Keepsafe, HighTower Advisors, Welkin Health, 1DocWay, 3T Biosciences, Synecor, Decent, Secure AI Labs, Reify Health. Over time, Skip Fleshman has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Skip Fleshman is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Hospitals, Delivery Service, Wellness, Women Founded, Apps, Women Led, Artificial Intelligence (AI), Information Technology (IT), Analytics, Internet of Things (IoT), Mobile, Medical Device, Software, Healthcare, Biotechnology, Computers, Network Security, Clinical Trials, FinTech, Privacy, Digital Health, Medical, Health Insurance, Machine Learning, Personal Health may find it worthwhile to explore potential connections with Skip Fleshman, as their portfolio suggests a familiarity and interest in this area.

Understanding Skip Fleshman’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.